{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:26:27Z","timestamp":1789453587258,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12012-020-09621-2","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T12:02:41Z","timestamp":1609588961000},"page":"314-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["QTc Prolongation in COVID-19 Patients Using Chloroquine"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-7498","authenticated-orcid":false,"given":"Matthijs L.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia W.","family":"van Gemeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hylke Jan","family":"Kingma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven F. L.","family":"van Lelyveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs J.","family":"Giezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"9621_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M., Cao, R., Zhang, L., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269\u2013271.","journal-title":"Cell Research"},{"key":"9621_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"X Yao","year":"2020","unstructured":"Yao, X., Ye, F., Zhang, M., et al. (2020). In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. https:\/\/doi.org\/10.1093\/cid\/ciaa237.","journal-title":"Clinical Infectious Diseases"},{"key":"9621_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","volume":"12","author":"M Huang","year":"2020","unstructured":"Huang, M., Tang, T., Pang, P., et al. (2020). Treating COVID-19 with chloroquine. Journal of Molecular Cell Biology, 12, 322\u2013325.","journal-title":"Journal of Molecular Cell Biology"},{"key":"9621_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends, 14, 72\u201373.","journal-title":"Bioscience Trends"},{"key":"9621_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6019.","journal-title":"JAMA"},{"key":"9621_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care, 57, 279\u2013283.","journal-title":"Journal of Critical Care"},{"key":"9621_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014","author":"AB Cavalcanti","year":"2020","unstructured":"Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., et al. (2020). Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. The New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2019014.","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"9621_CR8","doi-asserted-by":"publisher","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba, M. G. S., Val, F. F. A., Sampaio, V. S., et al. (2020). Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Network Open, 3(4), e208857. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8857.","journal-title":"JAMA Network Open"},{"issue":"20","key":"9621_CR9","first-page":"30431","volume":"S1547\u20135271","author":"L Jankelson","year":"2020","unstructured":"Jankelson, L., Karam, G., Becker, M. L., Chinitz, L. A., & Tsai, M. (2020). QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm, S1547\u20135271(20), 30431\u201330438.","journal-title":"Heart Rhythm"},{"key":"9621_CR10","unstructured":"Stichting Werkgroep Antibioticabeleid. (2020). Medicamenteuze behandelopties bij pati\u00ebnten met COVID-19 (infecties met SARS-CoV-2). [Medical treatment options in patients with COVID-19 (infection with SARS-CoV-2)]. Retrieved April 21, 2020, from https:\/\/swab.nl\/nl\/covid-19."},{"key":"9621_CR11","unstructured":"Nederlandse Vereniging voor Intensive Care. Handreiking infecties met COVID-19 op de intensive care\u2013 nr. 4. [Guide infectionswith COVID-19 on the intensive care nr. 4]. Retrieved April 21, 2020, from https:\/\/nvic.nl\/sites\/nvic.nl\/files\/20200316%20Update%204%20-%20Handreiking%20infecties_3.pdf."},{"key":"9621_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06022-5","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani, W., M\u00f8ller, M. H., Arabi, Y. M., et al. (2020). Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine. https:\/\/doi.org\/10.1007\/s00134-020-06022-5.","journal-title":"Intensive Care Medicine"},{"key":"9621_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White, N. J. (2007). Cardiotoxicity of antimalarial drugs. The Lancet Infectious Diseases, 7, 549\u2013558.","journal-title":"The Lancet Infectious Diseases"},{"key":"9621_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00891-1","author":"C Smit","year":"2020","unstructured":"Smit, C., Peeters, M. Y. M., van den Anker, J. N., & Knibbe, C. A. J. (2020). Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties. Clinical Pharmacokinetics. https:\/\/doi.org\/10.1007\/s40262-020-00891-1.","journal-title":"Clinical Pharmacokinetics"},{"key":"9621_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-017-2381-5","volume":"74","author":"CP Heemskerk","year":"2018","unstructured":"Heemskerk, C. P., Pereboom, M., van Stralen, K., et al. (2018). Risk factors for QTc interval prolongation. European Journal of Clinical Pharmacology, 74, 183\u2013191.","journal-title":"European Journal of Clinical Pharmacology"},{"key":"9621_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fphar.2020.00616","volume":"11","author":"A Tosaki","year":"2020","unstructured":"Tosaki, A. (2020). ArrhythmoGenoPharmacoTherapy. Frontiers in Pharmacology, 11, 616. https:\/\/doi.org\/10.3389\/fphar.2020.00616.","journal-title":"Frontiers in Pharmacology"},{"issue":"8","key":"9621_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/molecules25081834","volume":"25","author":"G Lentini","year":"2020","unstructured":"Lentini, G., Cavalluzzi, M. M., & Habtemariam, S. (2020). COVID-19, chloroquine repurposing, and cardiac safety concern: Chirality might help. Molecules, 25(8), 1834. https:\/\/doi.org\/10.3390\/molecules25081834.","journal-title":"Molecules"},{"key":"9621_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.26.114033","author":"G Li","year":"2020","unstructured":"Li, G., Sun, J., Li, Y., Shi, Y., Zhao, J., Zhang, T. Y., & Zhang, X. (2020). Enantiomers of chloroquine and hydroxychloroquine exhibit different activities against SARS-CoV-2 in vitro, evidencing s-hydroxychloroquine as a potentially superior drug for COVID-19. bioRxiv. https:\/\/doi.org\/10.1101\/2020.05.26.114033.","journal-title":"bioRxiv"},{"key":"9621_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.03.028","author":"DR Lakkireddy","year":"2020","unstructured":"Lakkireddy, D. R., Chung, M. K., Gopinathannair, R., et al. (2020). Guidance for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the heart rhythm society COVID-19 task force; electrophysiology section of the American College of Cardiology; and the electrocardiography and arrhythmias committee of the council on clinical cardiology, American Heart Association. Heart Rhythm. https:\/\/doi.org\/10.1016\/j.hrthm.2020.03.028.","journal-title":"Heart Rhythm"},{"key":"9621_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.03.024","author":"CI Wu","year":"2020","unstructured":"Wu, C. I., Postema, P. G., Arbelo, E., et al. (2020). SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. https:\/\/doi.org\/10.1016\/j.hrthm.2020.03.024.","journal-title":"Heart Rhythm"},{"key":"9621_CR21","unstructured":"Woosley, RL and Romero, KA. QT drug list. Retrieved April 15, 2020, from http:\/\/www.Crediblemedsorg\/."},{"key":"9621_CR22","first-page":"353","volume":"7","author":"HC Bazett","year":"1920","unstructured":"Bazett, H. C. (1920). An analysis of the time-relations of the electrocardiograms. Heart, 7, 353\u2013370.","journal-title":"Heart"},{"key":"9621_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia, L. S. (1920). Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Medica Scandinavica, 53, 469\u2013486.","journal-title":"Acta Medica Scandinavica"},{"key":"9621_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.18433\/J3ZD15","volume":"20","author":"CP Heemskerk","year":"2017","unstructured":"Heemskerk, C. P., Woldman, E., Pereboom, M., et al. (2017). Ciprofloxacin does not prolong the QTc interval: A clinical study in ICU patients and review of the literature. Journal of Pharmacy and Pharmaceutical Sciences, 20, 360\u2013364.","journal-title":"Journal of Pharmacy and Pharmaceutical Sciences"},{"key":"9621_CR25","first-page":"401","volume":"15","author":"EJ Schrijver","year":"2018","unstructured":"Schrijver, E. J., Verstraaten, M., van de Ven, P. M., et al. (2018). Low dose oral haloperidol does not prolong QTc interval in older acutely hospitalised adults: A subanalysis of a randomised double-blind placebo-controlled study. Journal of Geriatric Cardiology, 15, 401\u2013407.","journal-title":"Journal of Geriatric Cardiology"},{"key":"9621_CR26","unstructured":"European Medicines Agency. ICH Topic E14 the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Retrieved April 23, 2020, from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluation-qt\/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf."},{"key":"9621_CR27","doi-asserted-by":"publisher","first-page":"e23728","DOI":"10.1371\/journal.pone.0023728","volume":"6","author":"MT Blom","year":"2011","unstructured":"Blom, M. T., Bardai, A., van Munster, B. C., et al. (2011). Differential changes in QTc duration during in-hospital haloperidol use. PLoS ONE, 6, e23728.","journal-title":"PLoS ONE"},{"key":"9621_CR28","first-page":"636","volume":"19","author":"V Vancura","year":"2017","unstructured":"Vancura, V., Wichterle, D., Ulc, I., et al. (2017). The variability of automated QRS duration measurement. Europace, 19, 636\u2013643.","journal-title":"Europace"},{"key":"9621_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2125.1986.tb02876.x","volume":"22","author":"S Looareesuwan","year":"1986","unstructured":"Looareesuwan, S., White, N. J., Chanthavanich, P., et al. (1986). Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. British Journal of Clinical Pharmacology, 22, 31\u201336.","journal-title":"British Journal of Clinical Pharmacology"},{"key":"9621_CR30","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1371\/journal.pctr.0020006","volume":"2","author":"F Mzayek","year":"2007","unstructured":"Mzayek, F., Deng, H., Mather, F. J., et al. (2007). Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clinical Trials, 2, e6.","journal-title":"PLoS Clinical Trials"},{"key":"9621_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4269\/ajtmh.2006.74.407","volume":"74","author":"JA Cook","year":"2006","unstructured":"Cook, J. A., Randinitis, E. J., Bramson, C. R., & Wesche, D. L. (2006). Lack of a pharmacokinetic interaction between azithromycin and chloroquine. American Journal of Tropical Medicine and Hygiene, 74, 407\u2013412.","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"7\u20138","key":"9621_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12471-020-01429-7","volume":"28","author":"MPH van den Broek","year":"2020","unstructured":"van den Broek, M. P. H., M\u00f6hlmann, J. E., Abeln, B. G. S., et al. (2020). Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands Heart Journal, 28(7\u20138), 406\u2013409. https:\/\/doi.org\/10.1007\/s12471-020-01429-7.","journal-title":"Netherlands Heart Journal"},{"issue":"7\u20138","key":"9621_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12471-020-01462-6","volume":"28","author":"FS Sinkeler","year":"2020","unstructured":"Sinkeler, F. S., Berger, F. A., Muntinga, H. J., et al. (2020). The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Netherlands Heart Journal, 28(7\u20138), 418\u2013423. https:\/\/doi.org\/10.1007\/s12471-020-01462-6.","journal-title":"Netherlands Heart Journal"},{"key":"9621_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1834","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro, N. J., Yen, C. F., Shim, D. J., et al. (2020). Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1834.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"9621_CR35","doi-asserted-by":"publisher","first-page":"e008662","DOI":"10.1161\/CIRCEP.120.008662","volume":"13","author":"M Saleh","year":"2020","unstructured":"Saleh, M., Gabriels, J., Chang, D., et al. (2020). Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circulation: Arrhythmia and Electrophysiology, 13(6), e008662. https:\/\/doi.org\/10.1161\/CIRCEP.120.008662.","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"3","key":"9621_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.hroo.2020.06.002","volume":"1","author":"AR Sridhar","year":"2020","unstructured":"Sridhar, A. R., Chatterjee, N. A., Saour, B., et al. (2020). QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. Heart Rhythm O2, 1(3), 167\u2013172. https:\/\/doi.org\/10.1016\/j.hroo.2020.06.002.","journal-title":"Heart Rhythm O2"},{"key":"9621_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H., Tomashek, K. M., Dodd, L. E., et al. (2020). Remdesivir for the treatment of covid-19\u2014final report. New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"New England Journal of Medicine"},{"issue":"10236","key":"9621_CR38","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Zhang, D., Du, G., et al. (2020). Remdesivir in adults with severe COVID-19: A randomised double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569\u20131578. https:\/\/doi.org\/10.1016\/S0140-6736(20)31022-9.","journal-title":"The Lancet"},{"issue":"11","key":"9621_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner, C. D., Gottlieb, R. L., Criner, G. J., et al. (2020). Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA, 324(11), 1048\u20131057. https:\/\/doi.org\/10.1001\/jama.2020.16349.","journal-title":"JAMA"},{"key":"9621_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"Horby, P., Shen Lim, W., Emberson, J. R., et al. (2020). Dexamethasone in hospitalized patients with covid-19\u2014preliminary report. New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"9621_CR41","doi-asserted-by":"publisher","first-page":"e003264","DOI":"10.1161\/JAHA.116.003264","volume":"5","author":"B Vandenberk","year":"2016","unstructured":"Vandenberk, B., Vandael, E., Robyns, T., et al. (2016). Which QT correction formulae to use for QT monitoring? Journal of the American Heart Association, 5(6), e003264. https:\/\/doi.org\/10.1161\/JAHA.116.003264.","journal-title":"Journal of the American Heart Association"},{"key":"9621_CR42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.hrthm.2008.03.037","volume":"5","author":"PG Postema","year":"2008","unstructured":"Postema, P. G., De Jong, J. S., Van der Bilt, I. A., & Wilde, A. A. (2008). Accurate electrocardiographic assessment of the QT interval: Teach the tangent. Heart Rhythm, 5, 1015\u20131018.","journal-title":"Heart Rhythm"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09621-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-020-09621-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09621-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T10:10:23Z","timestamp":1616580623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-020-09621-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["9621"],"URL":"https:\/\/doi.org\/10.1007\/s12012-020-09621-2","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of the Spaarne Gasthuis (Haarlem\/Hoofddorp, the Netherlands). All patient data were processed anonymously, according to privacy legislation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}